Document › Details
Themis Bioscience GmbH. (2/24/10). "Press Release: Themis Bioscience Successfully Closes Seed-financing Round – EUR 1 Million for Company Start-up". Vienna.
|Organisation||Themis Bioscience GmbH|
|Organisation 2||Austria Wirtschaftsservice GmbH – aws|
|Index term||Themis Bioscience–Austria (govt): investment, 201002 seed financing €1m from Austria Wirtschaftsservice|
|Person||Tauber, Erich (Themis Bioscience GmbH 201505 CEO)|
|Person 2||Montanari, Bruno (Omnes Capital 201607 Partner)|
Themis Bioscience GmbH, an Austrian start-up biotechnology company, announces the succesful completion of its seed financing round. The company, founded in September 2009 by international vaccine experts, received one million Euro – the highest possible level of seed financing – from austria wirtschaftsservice (aws), Austria’s national promotional bank.
Themis Bioscience is using its vaccine technology Themaxyn™ – an innovative platform technology that enables effective development of vaccines with a favorable safety and efficacy profile – against tropical infectious diseases. The first product candidates include vaccines against dengue virus, chikungunya virus and fellow fever virus. These are all tropical diseases that have spread increasingly in recent decades, affecting travelers as well as growing population groups living in the endemic areas. There are no effective treatment options, and either outdated or no preventive vaccines are available for these diseases.
“Pioneering biotech companies, their succesful innovations and courageous entrepreneurship have built a solid biotechnology infrastructure in Austria and there are excellent instruments for the development and growth of biotechnology companies. This seed financing will enable us to build-up our company and use our technology rapidly and efficiently to develop vaccines”, says Themis founder and CEO Dr. Erich Tauber. Prior to founding Themis, he was Vice President of Product Development and Medical Officer of Intercell AG, and was responsible for the successful development of the company’s travel vaccine against Japanese Encephalitis.
“With Themis, the biotechnology community in Vienna has gained another promising player in the field of vaccine development. Both the management as well as the business concept strongly convinced our international expert board. We are looking forward to supporting Themis further development with our aws start-up financing tool “Seedfinancing””, said Michaela Fritz, the responsible investment manager at aws.
The vector-based technology will be tested in animal models by mid 2010. At the same time, Themis will further strengthen its financial basis by raising both private and public funds.
About dengue virus, chikungunya virus and yellow fever virus
Dengue fever is transmitted by various mosquitoes of the genus Aedes, carrying the dengue virus. The first documented epidemic occurred from 1779 to 1780 simultaneously in Asia, Africa and North America, demonstrating a worldwide distribution of at last 200 years.
The rapid population growth, urbanization and international air traffic have contributed to a dramatic increase in dengue disease in recent years. Today more than 2.5 billion people live in risk areas in the tropics and subtropics.
The WHO estimates 50 to 100 million illnesses annually, of which 250,000 to 500,000 represent the severe form, dengue haemorrhagic fever (DHF). Currently, there is no preventive vaccine or specific therapy. Chikungunya fever is a viral infection and is also transmitted by mosquitoes of the genus Aedes. This viral pathogen occurs in South and Southeast Asia, and in Africa south of the Sahara, but of note is especially a recent epidemic in Italy. Symptoms include a sudden onset of high fever, headache, conjunctivitis and muscle and joint pain and arthralgia. Currently, there is no preventive vaccine or specific therapy.
Yellow fever is an infectious disease found in tropical Africa and in tropical Central and South America, which is also transmitted by mosquitoes. According to the WHO, about 200,000 people are infected with yellow fever worldwide each year, of which roughly 30,000 die. The disease begins with flu-]like symptoms, with typical yellow fever involving a highly febrile phase of three to four days with nausea and vomiting (sometimes even with vomiting of blood), headache, back pain and yellowing of the skin (jaundice). A specific treatment for yellow fever does not exist.
Dr. Erich Tauber
Chief Executive Officer
Themis Bioscience GmbH,
Rudolf Sallinger 1,
Tel: 43 699 1022 22 65,
Record changed: 2016-07-11
More documents for Themis Bioscience GmbH
-  Themis Bioscience GmbH. (11/28/16). "Press Release: Themis Bioscience Successfully Closes 10 M EUR Financing Round". Vienna....
-  Themis Bioscience GmbH. (7/12/16). "Press Release: New Worldwide, Exclusive License Agreement Provides Broad Access to Institut Pasteur's Virus Vector Technology – Zika Vaccine Development Progressing with High Priority". Vienna....
-  Themis Bioscience GmbH. (5/5/15). "Press Release: Themis Bioscience Raises up to EUR 10 Million in Series B. New Board to Drive Partnerships and Commercialization of Product Pipeline". Vienna....
-  Themis Bioscience GmbH. (5/18/11). "Press Release: Themis Bioscience Completes Series A Financing Round – EUR 5 Million to Advance Promising Vaccine Candidates". Vienna....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)